Febuxostat (Uloric) and its problem with cardiovascular mortality

Last Updated on

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons. Febuxostat (Uloric) was approved by the American Food and Drug Administration (FDA) in 2009 for the chronic management of hyperuricemia in patients with gout. One condition of the approval of Febuxostat (Uloric) in 2009 was that a postmarketing safety study be conducted by Takeda Pharmaceuticals America, Inc. The postmarketing safety trial required by the FDA was called Cardiovascular Safety of Febuxostat (Uloric) and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES).
In March 2018 it was announced that this CARES trial found that Febuxostat (Uloric) was inexplicably linked to more cardiac deaths than was Allopurinol, the mainstay drug for patients with gout and cardiovascular disease. As a consequence, on January 10, 2019, the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee panelists discussed the potential biological mechanisms behind cardiovascular (CV) events associated with the use of Febuxostat (Uloric) and its seemingly heightened risk for unwanted cardiovascular events.

The panelists came to the conclusion that for the general population with gout, the benefits of Febuxostat (Uloric) would not outweigh the risks (particularly cardiovascular events) when compared to Allopurinol, one of the standard treatments in patients with gout. In contrast, they proposed that the benefits of urate-lowering Febuxostat (Uloric) outweigh its risks for selected gout patients, though only for unrestricted access only as a second-line therapy, mostly for individuals who have had a serious skin reaction to or otherwise “absolutely don’t tolerate” Allopurinol, the mainstay xanthine oxidase inhibitor for uric acid reduction.

In this context, it is noteworthy that Febuxostat (Uloric)’s label already warns of increased risk of gout flares with initiation of therapy, cardiovascular events, hepatic toxicity, and serious skin reactions. Panelists further recommended several regulatory actions such as an additional black box warning and a change in the indication to label Febuxostat (Uloric) as a second-line therapy after Allopurinol only. They kept it open, if even a recall of Febuxostat (Uloric) could be considered.

Further to the status at the time of this writing, the FDA has now added a “Boxed Warning” to the drug label of Febuxostat (Uloric) due to the obvious increased risk of death for patients under Febuxostat (Uloric) and introduce a new, strengthened patient Medication Guide. FDA  also limits the approved use of Uloric to certain patients who are not treated effectively or experience severe side effects with Allopurinol.  See here the according safety communication by the FDA as of February 02, 2019.

See here an video introductory to gout:

Print Friendly, PDF & Email

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


@peepso_user_1(thassodotcom) This was about time. That is what Boxed Warnings are for.
12 months ago 12 months ago

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • New therapy stops seizures in mouse model of rare childhood epilepsy February 20, 2020
    Seizure disorders in babies are frightening and heartbreaking. A new basic science breakthrough offers hope for a potential treatment for rare developmental and epileptic encephalopathies resulting from a single genetic mutation. The gene in question, called SCN8A, controls a sodium channel that allows neurons to transmit an electric signal. When this gene is mutated, these […]
  • Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers' February 20, 2020
    A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as "drivers"—variations in DNA sequences that lead to the development of cancer.
  • A deep dive into cellular aging February 20, 2020
    Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell's nucleus—and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes & Development, could lead […]
  • New model of C. elegans helps progress study of rare genetic disease February 20, 2020
    The IDIBELL Neurometabolic Diseases group, with international collaboration, has identified a model of chromosome X-linked adrenoleukodystrophy (X-ALD) in C. elegans. X-ALD is a rare disorder of the nervous system with no available treatment.
  • Half of transgender youth avoid disclosing gender identity to a health care provider February 20, 2020
    Researchers surveyed 153 transgender youths receiving gender-affirming care at a specialty clinic, and even in this relatively 'out' population, nearly half reported intentionally hiding their gender identity from a health care provider outside the clinic.
  • Fifty years of data show new changes in bird migration February 20, 2020
    A growing body of research shows that birds' spring migration has been getting earlier and earlier in recent decades. New research from The Auk: Ornithological Advances on Black-throated Blue Warblers, a common songbird that migrates from Canada and the eastern US to Central America and back every year, uses fifty years of bird-banding data to […]
  • New study supports the safety of varenicline February 20, 2020
    A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT). These findings confirm those of earlier clinical trials, providing […]
  • New study indicates amino acid may be useful in treating ALS February 20, 2020
    A naturally occurring amino acid is gaining attention as a possible treatment for ALS following a new study published in the Journal of Neuropathology & Experimental Neurology. It showed the amino acid, L-serine, successfully reduced ALS-like changes in an animal model of ALS. After exposure to the cyanobacterial neurotoxin, BMAA, vervets developed pathology similar to […]
  • Patients frequently refuse insulin therapy, delaying blood sugar control February 20, 2020
    Investigators from Brigham and Women's Hospital find that more than 40% of patients refuse a physician's recommendation of insulin therapy. The study also finds that patients who decline insulin therapy had worse blood sugar control and it took them significantly longer to lower their blood sugar levels than patients who began insulin therapy.